NCT07838220RecruitingPhase 1
A Study of IBI3016 in Japanese Participants
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Administration of IBI3016 in Japanese Participants With Mild to Moderate Hypertension
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 13 Sept 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 30 Jan 2027
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Diseases
- High blood pressure
- NCT number
- NCT07838220
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 30
- From 1 Aug 2026 to the primary completion date, 30 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 4\. With diseases that require treatment with renin-angiotensin-aldosterone system (RAAS) inhibitors other than hypertension at screening;
- 5\. Presence of serious active and uncontrolled physical conditions or medical history, which may be in a dangerous state during the use of the study drug, or interfere with the interpretation of efficacy and safety data of this study, as judged by the investigator prior to randomization
Other illness
- 1\. Participants with secondary hypertension, including but not limited to the following conditions: obstructive sleep apnea;
- 2\. History of orthostatic hypotension
- 3\. Current or history of intolerance to AECI, ARB, ARNI or direct renin inhibitor
Who the study is looking for
- 1\. Male or female participants aged 18-75 years (inclusive) at the time of informed consent;
- 2\. Must have been born in Japan, and their biological parents and grandparents must have been of Japanese origin;
- 3\. Office mean sitting SBP≥ 140 mmHg and \< 170 mmHg at screening
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical Corporation Heishinkai OPHAC Hospital Coordinator of this site? Confirm its status | Osaka | Japan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.